DNER and triple-A syndrome: BET inhibitors such as JQ-1, and related small molecules that interfere with SEs, are effective in animal models of atherosclerosis, AAA [73], inflammatory renal disease [73], PAH [60], and carotid intimal hyperplasia [56], highlighting the promise of such epigenetic modifiers for the treatment of human vascular diseases.